Population PK – PD Modeling of Danicopan Add‐On Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria Treated With Ravulizumab or Eculizumab

Danicopan is a first-in-class orally administered complement factor D inhibitor, approved as an add-on therapy to ravulizumab or eculizumab for the treatment of clinically significant extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). Population pharmacokinetics (PK) and pharmacodynamics (PK-PD) modeling was used to characterize danicopan PK and to evaluate the relationship between steady-state exposure and alternative pathway (AP) activity using data from health